• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE® VIABAHN® ENDOPROSTHESIS WITH PROPATEN BIOACTIVE SURFACE; STENT, SUPERFICIAL FEMORAL ARTERY

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE® VIABAHN® ENDOPROSTHESIS WITH PROPATEN BIOACTIVE SURFACE; STENT, SUPERFICIAL FEMORAL ARTERY Back to Search Results
Device Problems Adverse Event Without Identified Device or Use Problem (2993); Insufficient Information (3190)
Patient Problem Thrombosis/Thrombus (4440)
Event Date 07/05/2020
Event Type  Injury  
Manufacturer Narrative
The author was contacted to ask for more details like event dates, serial no's, implant dates as well as patient data and possible root causes.Date of event was determined as date when literature article was accepted, here july 5, 2020.As patient age the mean age 68 years was determined and as gender male as mentioned in the article.Cbas® heparin surface incorporates cbas-heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.
 
Event Description
The following literature was reviewed: ¿stent-grafts are the best way to treat complex in-stent restenosis lesions in the superficial femoral artery: 24-month results from a multicenter randomized trial¿ published by marc bosiers in the journal of cardiovascular surgery 2020 october;61(5):617-25.This clinical trial aims to evaluate the outcome (up to 24-months) of the treatment of in-stent restenotic or reoccluded lesions in the femoropopliteal arteries, by comparing the treatment of the gore® viabahn® endoprosthesis with propaten bioactive surface (viabahn-device) with a standard pta treatment.A total of 83 patients meeting inclusion and exclusion criteria have been enrolled in this prospective, randomized, multicenter, controlled study in 7 sites between june 2010 and february 2012.Among the 83 patients, 3 experienced device-related adverse events within 30 days: occlusions of the study lesion.
 
Manufacturer Narrative
Requests were emailed to the author to provide additional information like patient information, serial numbers, dates of procedure, onset date of occlusion, date of reintervention, imaging series, etc.The requests remained unanswered.The serial numbers remain unknown, therefore a review of the manufacturing records could not be performed.The devices remain implanted in the patients, therefore device evaluations could not be performed.With no additional information provided, gore is unable to perform further investigations of this complaint.This investigation is considered complete, the cause of the complaint was unable to be determined.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE® VIABAHN® ENDOPROSTHESIS WITH PROPATEN BIOACTIVE SURFACE
Type of Device
STENT, SUPERFICIAL FEMORAL ARTERY
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL ECHO RIDGE B/P
3250 w. kiltie lane
flagstaff AZ 86005
Manufacturer Contact
gunter marte
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key12296334
MDR Text Key265798221
Report Number2017233-2021-02227
Device Sequence Number1
Product Code NIP
Combination Product (y/n)Y
Reporter Country CodeBE
PMA/PMN Number
P040037
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature,Health Professional
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 12/23/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 07/12/2021
Initial Date FDA Received08/09/2021
Supplement Dates Manufacturer Received11/30/2021
Supplement Dates FDA Received12/23/2021
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age68 YR
Patient SexMale
-
-